What You Should Know:
– Today, leading US health systems, including Advocate Health, CommonSpirit Health, Henry Ford Health, Northwell Health, Providence, and Trinity Health, announce the Truveta Genome Project, an innovative collaboration to generate genetic data on tens of millions of consented and de-identified volunteers, creating the largest and most diverse database of genotypic and phenotypic information ever assembled.
– At over ten times the scale of previous endeavors, this groundbreaking project ensures comprehensive representation across ancestries, ethnicities, genders, and other social drivers of health, unlocking profound insights into how genetics impact health. Truveta and its member health systems will partner with the Regeneron Genetics Center® (RGC) to sequence the exomes of the first ten million volunteers. Microsoft Azure will be the exclusive cloud provider for the Truveta Genome Project.
Truveta Genome Project: Accelerating the Science of Humanity with AI and Genomics
Truveta, a collective of 30 leading U.S. health systems, is dedicated to “Saving Lives with Data” by delivering the most comprehensive, timely, and clean regulatory-grade electronic health record (EHR) data for rigorous research. Founded in 2020, Truveta’s collaboration with health systems has created Truveta Data, a de-identified dataset representing over 120 million patients, driving breakthroughs in cardiovascular, neurology, oncology, metabolic, and other medical fields.
The Truveta Genome Project: Unlocking Genomic Insights
The Truveta Genome Project, one of the world’s largest and most diverse genomic databases, integrates patient consented biospecimens linked to anonymized medical records. These biospecimens, obtained from routine lab tests, are sent to Regeneron Genetics Center (RGC) for sequencing and stored for future multi-omics research. Truveta Data combines genotypic and phenotypic insights to power AI-driven drug discovery, optimize clinical trials, and develop diagnostics for targeted therapies.
Key Features of the Truveta Genome Project:
- AI-Driven Data Transformation: Utilizes the Truveta Language Model, a multi-modal AI model built on Microsoft Azure, to transform billions of data points with industry-leading normalization and privacy safeguards.
- Daily Data Updates: Ensures availability of the most complete, timely, and clean regulatory-grade data for research.
- Advanced Multiomic Research: Enables follow-up studies on population exome data to discover genetic and environmental influences on health.
Transforming Research and Patient Care
By addressing historical limitations in genomic medicine, Truveta’s platform accelerates advancements in disease prevention, diagnosis, and treatment. Its applications include:
- Drug Discovery: Partnering with life sciences organizations to identify genetic disease markers, enabling targeted therapies and biomarker discovery.
- Improving Clinical Trials: Enhancing efficiency by identifying patient populations most likely to respond to treatments, reducing costs, and improving success rates.
- Value-Based Care: Collaborating with healthcare innovators to transform care delivery and improve patient outcomes.
Strategic Partnerships and Investments
To realize its bold vision, Truveta has secured over $320 million in preferred equity funding, with significant investments from Regeneron ($119.5 million) and Illumina ($20 million). This builds on Microsoft’s earlier strategic investment. Regeneron’s expertise in genetic research and Illumina’s leadership in DNA sequencing position Truveta to advance next-generation healthcare solutions.
Driving a Global Genomic Revolution
“Much like registering as an organ donor is a simple act of service with profound impact, the Truveta Genome Project allows individuals to anonymously contribute to advancing humanity’s understanding of biology,” said Terry Myerson, CEO and co-founder of Truveta. Discoveries from smaller datasets have already yielded breakthroughs in heart disease prevention and congenital deafness treatments; the scale of Truveta’s dataset holds even greater promise for the future of precision medicine.
Through its innovative integration of AI and genomics, Truveta is not only advancing drug discovery but also empowering healthcare systems to enhance value-based care, ultimately improving health outcomes for families and communities worldwide.
